Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Short-term Investments (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Short-term Investments for 8 consecutive years, with $469.5 million as the latest value for Q1 2026.

  • Quarterly Short-term Investments fell 0.89% to $469.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $469.5 million through Feb 2026, down 0.89% year-over-year, with the annual reading at $346.0 million for FY2025, 30.75% down from the prior year.
  • Short-term Investments for Q1 2026 was $469.5 million at Nurix Therapeutics, up from $346.0 million in the prior quarter.
  • The five-year high for Short-term Investments was $499.6 million in Q4 2024, with the low at $183.2 million in Q1 2022.
  • Average Short-term Investments over 5 years is $312.1 million, with a median of $296.9 million recorded in 2022.
  • Peak annual rise in Short-term Investments hit 143.98% in 2025, while the deepest fall reached 30.75% in 2025.
  • Over 5 years, Short-term Investments stood at $244.7 million in 2022, then dropped by 4.65% to $233.3 million in 2023, then surged by 114.16% to $499.6 million in 2024, then crashed by 30.75% to $346.0 million in 2025, then surged by 35.71% to $469.5 million in 2026.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $469.5 million, $346.0 million, and $350.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.